catalog number :
MBS2059559
products full name :
FITC-Linked Polyclonal Antibody to Complement Component 9 (C9)
products short name :
[Complement Component 9 (C9)]
other names :
[complement component C9 preproprotein; Complement component C9; complement component C9; complement C9]
products gene name :
[C9]
other gene names :
[C9; C9; C9D; ARMD15]
purity :
Antigen-specific Affinity Chromatography
form :
Supplied as a solution form in PBS, pH 7.4 containing 0.02% NaN 3 , 50% glycerol.
concentration :
0.42 mg/mL
storage stability :
Storage: Avoid repeated freeze/thaw cycles. Store at 4ºC for frequent use. Aliquot and store at -20ºC for 12 months. Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the
expiration date under appropriate storage condition.
tested application :
Western Blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunoprecipitation (IP)
app notes :
Western Blotting: 0.5-2 ug/mL; 1:200-800. Immunohistochemistry : 5-20 ug/mL; 1:20-80. Immunocytochemistry: 5-20 ug/mL; 1:20-80. Optimal working dilutions must be determined by end user.
other info1 :
Organism Species: Homo sapiens (Human). Source: Antibody Labeling. Label: FITC. Traits: Liquid. Immunogen: Recombinant C9 (Gln22-His265)expressed in E.coli.
other info2 :
Unconjugated Antibody: The unconjugated antibody version of this item is also available as catalog #MBS2028726
ncbi acc num :
NP_001728.1
ncbi gb acc num :
NM_001737.4
ncbi pathways :
Amoebiasis Pathway (167324); Amoebiasis Pathway (167191); Complement Activation, Classical Pathway (198823); Complement And Coagulation Cascades Pathway (198880); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); Complement Cascade Pathway (106405); Immune System Pathway (106386); Innate Immune System Pathway (106387); Prion Diseases Pathway (101144)
ncbi summary :
This gene encodes the final component of the complement system. It participates in the formation of the Membrane Attack Complex (MAC). The MAC assembles on bacterial membranes to form a pore, permitting disruption of bacterial membrane organization. Mutations in this gene cause component C9 deficiency. [provided by RefSeq, Feb 2009]
uniprot summary :
C9: Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC. Defects in C9 are a cause of complement component 9 deficiency (C9D). A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. Belongs to the complement C6/C7/C8/C9 family. Protein type: Apoptosis; Extracellular matrix; Membrane protein, integral; Membrane protein, multi-pass. Chromosomal Location of Human Ortholog: 5p13.1. Cellular Component: cytoplasm; extracellular region; integral to plasma membrane; plasma membrane. Biological Process: hemolysis by symbiont of host red blood cells; regulation of complement activation. Disease: Complement Component 9 Deficiency; Macular Degeneration, Age-related, 15